Evidence map›Paper›PMID 37510207›Full record

ReviewDiagnostics (Basel, Switzerland)2023

The Predictive Capabilities of Artificial Intelligence-Based OCT Analysis for Age-Related Macular Degeneration Progression-A Systematic Review.

George Adrian Muntean, Anca Marginean, Adrian Groza, Ioana Damian, Sara Alexia Roman, Mădălina Claudia Hapca, Maximilian Vlad Muntean, Simona Delia Nicoară

Open access · goldAbstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. A post-hoc analysis of intravitreal aflibercept-treated nAMD patients from ARIES & ALTAIR: predicting treatment intervals and frequency for aflibercept treat-and-extend therapy regimen using machine learning.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

George Adrian MunteanDepartment of Ophthalmology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Emergency County Hospital, 400347 Cluj-Napoca, Romania.ORCID 0000-0003-1567-254X
Anca MargineanDepartment of Computer Science, Technical University of Cluj-Napoca, 400114 Cluj-Napoca, Romania.ORCID 0000-0001-8426-588X
Adrian GrozaDepartment of Computer Science, Technical University of Cluj-Napoca, 400114 Cluj-Napoca, Romania.ORCID 0000-0003-0143-5631
Ioana DamianDepartment of Ophthalmology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Emergency County Hospital, 400347 Cluj-Napoca, Romania.ORCID 0000-0003-4301-7112
Sara Alexia RomanFaculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.ORCID 0009-0002-5856-1487
Mădălina Claudia HapcaDepartment of Ophthalmology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Emergency County Hospital, 400347 Cluj-Napoca, Romania.ORCID 0000-0002-8391-9754
Maximilian Vlad MunteanPlastic Surgery Department, "Prof. Dr. I. Chiricuta" Institute of Oncology, 400015 Cluj-Napoca, Romania.ORCID 0000-0003-0709-8779
Simona Delia NicoarăDepartment of Ophthalmology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Emergency County Hospital, 400347 Cluj-Napoca, Romania.ORCID 0000-0002-7886-2044
Iuliu Hațieganu University of Medicine and Pharmacy · ROTechnical University of Cluj-Napoca · ROInstitute of Oncology Prof. Dr. Ion Chiricuta · RO

Funding

Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii PN-III-P2-2.1-PED-2021-2709
6 · The paper itself

Abstract

The era of artificial intelligence (AI) has revolutionized our daily lives and AI has become a powerful force that is gradually transforming the field of medicine. Ophthalmology sits at the forefront of this transformation thanks to the effortless acquisition of an abundance of imaging modalities. There has been tremendous work in the field of AI for retinal diseases, with age-related macular degeneration being at the top of the most studied conditions. The purpose of the current systematic review was to identify and evaluate, in terms of strengths and limitations, the articles that apply AI to optical coherence tomography (OCT) images in order to predict the future evolution of age-related macular degeneration (AMD) during its natural history and after treatment in terms of OCT morphological structure and visual function. After a thorough search through seven databases up to 1 January 2022 using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, 1800 records were identified. After screening, 48 articles were selected for full-text retrieval and 19 articles were finally included. From these 19 articles, 4 articles concentrated on predicting the anti-VEGF requirement in neovascular AMD (nAMD), 4 articles focused on predicting anti-VEGF efficacy in nAMD patients, 3 articles predicted the conversion from early or intermediate AMD (iAMD) to nAMD, 1 article predicted the conversion from iAMD to geographic atrophy (GA), 1 article predicted the conversion from iAMD to both nAMD and GA, 3 articles predicted the future growth of GA and 3 articles predicted the future outcome for visual acuity (VA) after anti-VEGF treatment in nAMD patients. Since using AI methods to predict future changes in AMD is only in its initial phase, a systematic review provides the opportunity of setting the context of previous work in this area and can present a starting point for future research.

Indexed as

age-related macular degenerationdeep learningmachine learningpredictionprogression

Identifiers

PMID37510207
PMCPMC10378064
OpenAlexW4385247369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.